We work with biotechnology and technology companies, philanthropic supporters, research colleagues and policymakers to accelerate scientific advances and extend the reach of our discoveries. It can take a decade or more for a new medicine to evolve from a finding in a research lab through clinical trials and approval. Our alliances help expedite the process by combining the financial, scientific and business expertise of multiple collaborators.
Arix Bioscience is a London-based venture capital firm that supports innovation in the life sciences and health care. Fred Hutch has formed a three-way collaboration with Arix and Hamburg-based drug discovery and development company Evotec SE to speed the development of new cancer and infectious disease drugs through the formation of new companies. The collaboration is called LAB591.
Evotec SE is a global drug discovery alliance and development partnership company whose R&D initiatives build bridges between cutting-edge science and transformative projects that help patients outside the research setting. It is a collaborator with Fred Hutch and Arix Bioscience in LAB591, a program launched in 2018 to speed the development of new cancer and infectious disease drugs through the formation of new companies.
Juno Therapeutics was founded in 2013 as a collaboration between Fred Hutch, Memorial Sloan-Kettering Cancer Research Center and Seattle Children’s Research Institute, combining cutting-edge immunotherapy expertise from all three institutions. Juno (now a Celgene company) is funding preclinical and clinical research at Fred Hutch to develop the next generation of immunotherapies for colorectal cancer, blood cancers and certain sarcomas.
Takeda is global pharmaceutical company based in Japan that develops new therapeutic drugs in the areas of oncology, gastroenterology and neuroscience. In 2018, Takeda entered into a research alliance with Fred Hutch, the University of Washington and Seattle Children’s Research Institute to take promising biological targets and accelerate development of candidate drugs that can benefit patients. The collaboration is known as the Seattle Partnership for Research on Innovative Therapies (SPRInT).
Discoveries made in Fred Hutch labs have led to dozens of licensing agreements and startup businesses, including biotechnology companies that are developing cutting-edge therapies and diagnostics.